To observe regulating effect of yangzhengxiaoji capsule on primary hepayic carcinoma patients treated by interventional hepatic artery perfusion embolism. Methods: A total of 457 patients were randomly divided into two groups. Treatment group: 232 cases of oral yangzhengxiaoji capsule， (four pieces at a time， three times a day， taken orally with warm water 30 min after meal) + hepatic artery chemotherapy embolism; control group: 225 cases that use hepatic artery chemotherapy embolism only. Medicine of both groups was DDP+ADM and the course lasted four weeks. Results: Treatment group and control group had no significant differences in treatment efficiency (P>0.05). The index before and after experiment in each group showed significant changes， and is of statistical significance (P<0.05）. Compared with control group， all liver function indicator in the treatment group， except for PT， all showed significant differences（P<0.05）. Treatment group showed no obvious adverse reactions compared with control group. Conclusion: Yangzhengxiaoji capsule with hepatic artery chemotherapy embolism is effective in improving liver function in patients with primary hepayic carcinoma. No obvious adverse reactions have been found thus is suitable for clinical application.